FDA warned Neoteric Cosmetics and parent Scott's Liquid Gold that ALPHA Skin Care Dual Action Fade Cream, a hydroquinone skin lightener, is an unapproved and misbranded drug.
What happened
FDA reviewed the ALPHA® SKIN CARE Dual Action Fade Cream label and the company website (neotericcosmetics.com) rather than doing an inspection. The label and web pages describe the product as a skin lightener that fades dark spots and contains 2% hydroquinone, which makes it a drug. Because FDA determined in a 2006 proposed rule that over-the-counter skin bleaching drugs are not generally recognized as safe and effective, the product needed an approved new drug application after September 23, 2020, and it has none.
What FDA found
The skin lightening cream is a new drug sold without an FDA-approved new drug application.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug that does not meet the requirements of section 505G for drugs marketed without approval.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Shipping this product across state lines is prohibited because it is an unapproved drug.
Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)Shipping this misbranded product across state lines is prohibited.
Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)The label and website claims show the product is intended to treat skin and change its structure or function, which makes it a drug.
21 CFR 201.128
What FDA wants
Respond in writing within 15 working days to the Office of Unapproved Drugs and Labeling Compliance (FDAADVISORY@fda.hhs.gov) describing what you have done to fix the violations and prevent them from recurring. If you cannot fully correct them in that time, give your reasons and a completion schedule.
Who should pay attention
- retailers and online marketplaces that stock skin lightening or fade creams
- brands selling hydroquinone products as over-the-counter drugs
- contract manufacturers making skin bleaching creams
This is a summary. Read the original letter on fda.gov.